Previous 10 | Next 10 |
New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patie...
ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell Lymphoma ALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in...
Poseida has built a non-viral genome engineering platform to develop safer cell therapies in oncology. This platform could enable outpatient use and expand the number of patients who can receive a cell therapy as well as bringing in substantial partnerships. Poseida's lead drug ca...
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) ther...
Allogene was hit with a clinical hold for the entirety of their allogeneic CAR T cell pipeline several days ago. The cause of the clinical hold was a chromosomal abnormality found in the CAR T cells within the patient. The possible ramifications of this clinical hold could affect ...
After the Food and Drug Administration paused Allogene Therapeutics ' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. It has rebounded 31% this week through Thursday, according to data from S&P Global Market Intelligence . That still leaves it down 30% s...
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer drugs mark...
Gainers: Hyzon Motors HYZN +5%. Avadel Pharmaceuticals (NASDAQ:AVDL) +4%. Allogene Therapeutics (NASDAQ:ALLO) +4%. Latch (NASDAQ:LTCH) +2%. Old National Bancorp (NASDAQ:ONB) +2%. Losers: Xiaobai Maimai (NASDAQ:HX) -4%. Clarus Therapeutics Holdings (NASDAQ:CRXT) -4%. Relay Thera...
Adding to post-market losses on Tuesday, CRISPR Therapeutics (NASDAQ:CRSP) has slipped another ~8.2% in early hours after the company’s gene-edited allogeneic CAR-T cell therapy CTX110 failed to excite investors with data from an early-stage trial in CD19+ B-cell maligna...
The situation around the clinical hold is unclear and will take at least a few months to resolve. The risk-reward opportunity is very high. I am taking a risk and buying. For further details see: Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger ® Technology to Optimize CAR T Cell Expansion and Pe...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participat...